Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells
详细信息 查看全文
- 作者：Gustavo J. Melena ; b ; Lidia Franco-Luzó ; nc ; David Ruanob ; d ; Á ; frica Gonzá ; lez-Murilloa ; b ; Arantzazu Alfrancae ; Fernando Cascof ; Á ; lvaro Lassalettab ; d ; Mercedes Alonsog ; Luí ; s Maderob ; d ; Ramó ; n Alemanyh ; Javier Garcí ; a-Castroe ; Manuel Ramí ; rezb ; d ; manuel.ramirez@salud.madrid.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：Neuroblastoma ; Oncolytic virotherapy ; Mesenchymal stem cells ; Immune response ; Cell migration
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 February 2016
- 年：2016
- 卷：371
- 期：2
- 页码：161-170
- 全文大小：1224 K
文摘
- m" id="list_ulist0010">
- •
First-in-humans, first-in-children use of MSCs as carriers for oncolytic virotherapy.
- •
This strategy allows administering very high amount of oncolytic virus with minimum toxicities.
- •
Pre-therapy T cell status and T effector responses were important aspects associated to the outcome.
- •
The presence of MSCs in the medicine product may prevent antioncovirus immune responses.